Find Oncology Drugs in Phase III Clinical Development in SPAIN

Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

Isofol's drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC) in the USA, Canada, Europe, Australia and now also in Japan.

Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

Isofol's drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC).

Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

Deal Size: $1,000.0 million Upfront Cash: $200.0 million

Deal Type: Licensing Agreement January 22, 2020

Details:

PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.